Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Stemline Therapeutic 750 LEXINGTON AVENUE ELEVENTH FLOOR NEW YORK NY 10022 USA

P: 646-502-2311 F: 646-389-0968

Description:

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 670,329
Shares Outstanding, K 43,956
Annual Sales, $ 500 K
Annual Net Income, $ -85,020 K
Last Quarter Sales, $ 13,010 K
Last Quarter Net Income, $ -16,840 K
60-Month Beta 1.29
% of Insider Shareholders 13.10%
% of Institutional Shareholders 80.08%
Float, K 38,198
% Float 86.90%

Growth:

1-Year Return -0.23%
3-Year Return 106.08%
5-Year Return 34.84%
5-Year Revenue Growth 614.29%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/02/19
Earnings Per Share ttm -2.80
EPS Growth vs. Prev Qtr 42.47%
EPS Growth vs. Prev Year 36.36%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

STML Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -6.15
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -116.58
Return-on-Assets (Before Tax) -89.96
Profit Margin % -17,004.00
Net Margin % N/A
Debt/Equity 0.01
Price/Sales 1,268.57
Price/Cash Flow N/A
Price/Book 6.25
Book Value/Share 2.31
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar